Arbutus Biopharma Corporation
ABUS
Jodie situation report
Arbutus Biopharma Corporation's move is being confirmed by its market group.
No new filing conclusion is available. 23 of 23 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- At least 15 of 23 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as REPL begins moving with the group.
Invalidation: The live read weakens if participation falls to 8 of 23 members or fewer.
Who this business touches
The relationships behind ABUS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
ROIVRoivant Sciences Ltd.partnerMay 29, 2025 ▾
“More than 550 issued patents and pending patent applications worldwide as of March 31, 2025, including patents directed to: • lipid structures, including cationic and PEG-lipids • particle compositions, including ranges of lipid ratios for nucleic acid-contai…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ABUS is currently a Participant in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.